What is it about?

Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. This review summarizes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

Featured Image

Read the Original

This page is a summary of: Alogliptin benzoate for management of type 2 diabetes, Vascular Health and Risk Management, April 2015, Taylor & Francis,
DOI: 10.2147/vhrm.s68564.
You can read the full text:

Read

Contributors

The following have contributed to this page